J. Matouš

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

M. A. Hussein, James R. Berenson, Rubén Niesvizky et al. · Haematologica · 2010 · 141 citations · Full text

Immunology, Observed Safety Profile, Pharmacotherapy +18

Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

Barbara Pro, Ranjana H. Advani, Pauline Brice et al. · Journal of Clinical Oncology · 2011 · 27 citations

Hematological Malignancy, Lymphoid Neoplasia, Refractory Salcl +15

A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.

James R. Berenson, J. Matouš, Delina Ferretti et al. · Blood · 2005 · 11 citations

Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study

J. Matouš, Jeffrey Letzer, Peter J. Rosen et al. · Journal of Clinical Oncology · 2009 · 10 citations

Immunology, Pathology, Vertical Study +19